Aerosolized Liposomal Amikacin and Laryngeal Injury
- PMID: 34488977
- PMCID: PMC8579316
- DOI: 10.1016/j.chest.2021.05.050
Aerosolized Liposomal Amikacin and Laryngeal Injury
Comment in
-
Response.Chest. 2021 Sep;160(3):e317-e318. doi: 10.1016/j.chest.2021.05.051. Chest. 2021. PMID: 34488978 No abstract available.
Comment on
-
Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium avium Complex Infection.Chest. 2021 Apr;159(4):e185-e187. doi: 10.1016/j.chest.2020.11.045. Epub 2021 Apr 6. Chest. 2021. PMID: 34022015
References
-
- Axiotakis L.G., Jr., Enver N., Keating C.L., Pitman M.J. Laryngeal injury due to amikacin inhalation for refractory mycobacterium avium complex infection. Chest. 2021;159(4):e185–e187. - PubMed
-
- Griffith D.E., Eagle G., Thomson R., et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198(12):1559–1569. - PubMed
-
- Voulgari P.V., Papazisi D., Bai M., Zagorianakou P., Assimakopoulos D., Drosos A. Laryngeal involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(5):321–325. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources